kff 2025 employer health benefits survey glp-1 coverage Drug costs outpace hospital prices in plans Employers across America are dropping

N Engl J Med (2016) 375(4):31122

This glucagon-like peptide-1 (GLP-1) receptor agonist encourages insulin secretion from the pancreas, slows gastric emptying, and reduces appetite, resulting in higher energy expenditure and lower food consumption

In some cases, a dermatologist can make a preliminary diagnosis based on a physical examination

For instance, Kaiser Permanente plans to revise its coverage criteria starting January 1, 2025, leading to inquiries about whether Kaiser covers weight loss drugs, as it will exclude coverage for GLP-1 medications when prescribed exclusively for reducing body mass in patients with a BMI under 40